Early Laser for Burn Scars (ELABS) - Randomised controlled trial of pulsed dye laser treatment and standard care versus standard care alone for the treatment of hypertrophic burn scars

Mark P. Brewin, Sharon Docherty, Vanessa Heaslip, Shelley Rhodes, Obioha C. Ukoumunne, Naomi C. Burnett-Fry, Katie Breheny, Jonathon M. Pleat, Kate M. Attrill, Kayvan Shokrollahi, Quentin Frew, Christopher J. Lewis



PII: S0305-4179(25)00129-9

DOI: https://doi.org/10.1016/j.burns.2025.107500

Reference: JBUR107500

To appear in: *Burns* Accepted date: 11 April 2025

Please cite this article as: Mark P. Brewin, Sharon Docherty, Vanessa Heaslip, Shelley Rhodes, Obioha C. Ukoumunne, Naomi C. Burnett-Fry, Katie Breheny, Jonathon M. Pleat, Kate M. Attrill, Kayvan Shokrollahi, Quentin Frew and Christopher J. Lewis, Early Laser for Burn Scars (ELABS) - Randomised controlled trial of pulsed dye laser treatment and standard care versus standard care alone for the treatment of hypertrophic burn scars, *Burns*, (2025) doi:https://doi.org/10.1016/j.burns.2025.107500

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Crown Copyright © 2025 Published by Elsevier Ltd.

# Title

# Early Laser for Burn Scars (ELABS) - Randomised controlled trial of pulsed dye laser treatment and standard care versus standard care alone for the treatment of hypertrophic burn scars

# Authors

Mark P. Brewin<sup>a</sup>, Sharon Docherty<sup>b</sup>, Vanessa Heaslip<sup>c</sup>, Shelley Rhodes<sup>d</sup>, Obioha C. Ukoumunne<sup>d</sup>, Naomi C. Burnett-Fry<sup>d</sup>, Katie Breheny<sup>e</sup>, Jonathon M. Pleat<sup>f</sup>, Kate M. Attrill<sup>g</sup>, Kayvan Shokrollahi<sup>h</sup>, Quentin Frew<sup>i</sup>, Christopher J. Lewis<sup>j</sup>

<sup>a</sup> Salisbury Laser Clinic, Salisbury NHS Foundation Trust, Wiltshire, UK

<sup>b</sup> Bournemouth University, Dorset, UK

<sup>c</sup> University of Salford, Greater Manchester, UK

<sup>d</sup> University of Exeter, Devon, UK

<sup>e</sup> North Bristol NHS Trust, Bristol, UK

<sup>f</sup> University of Bristol, Bristol, UK

<sup>g</sup> Chelsea and Westminster NHS Foundation Trust, London, UK

<sup>h</sup> Mersey and West Lancashire Teaching Hospitals NHS Trust, Merseyside, UK

<sup>i</sup> Mid and South Essex NHS Foundation Trust, Essex, UK

<sup>j</sup> Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Corresponding Author: Dr. Mark P Brewin, mark.brewin@nhs.net

### Abstract

**Background** Hypertrophic burn scarring (HBS) is described as "the greatest unmet challenge after burn injury". This ELABS trial hypothesised that early pulsed dye laser (PDL) treatment of HBS improves both scar quality and quality of life (QoL).

**Methods** A parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of PDL was undertaken at seven centres in the UK. Patients were eligible if their burn injury was within three months of wound healing, and ineligible either with history of keloid scarring or aged <16 years. A total of 153 (77 Male, 76 Female) participants were recruited between Nov 17, 2021, and Jun 30, 2023, and were randomised using software in a 1:1 ratio stratified by study centre; 138 (69 each arm) were included in the final complete-case analysis. Both study arms received standard care, and the intervention arm received three PDL treatments. The primary outcome was patient-rated scar quality (POSAS) at six months. The trial was registered with International Standard Randomised Controlled Trial Number registry (ISRCTN14392301).

**Findings** Early PDL showed a statistically significant improvement in patient-rated scar quality (p=0.041) and the secondary outcome, participant's perception of change in scar quality (p=0.01) at six months. There were no statistically significant differences for Quality-of-Life, observer-rated POSAS scar quality and colour measurement. Early PDL is not cost-effective at 6 months follow-up for the willingness-to-pay threshold of £20,000 per Quality-Adjusted-Life-Year (QALY). There were no unexpected adverse events related to the intervention.

**Interpretation** Early PDL treatment of HBS is safe and shows improvement for patient-rated scar quality but not QoL at six months. As scar maturation is prolonged and dynamic, longer-term follow-up of upwards of two years is required both to understand the eventual clinical effect on scar outcome and to make any definitive conclusion concerning cost-effectiveness.

Funding National Institute for Health and Care Research (NIHR201080, United Kingdom)

Keywords: Burn injury, Hypertrophic Scar, POSAS, Pulsed Dye Laser, Quality-of-Life, RCT

# Introduction

Hypertrophic scarring is characterised by being red, raised and firm and, in contrast to keloids, remains within the borders of the original wound. It occurs following skin insults associated with excessive inflammation, but surgical, traumatic or burn-related wounds are more common causes. More than 100 million people worldwide are thought to have acquired scars due to these injuries.(1)

Survival rates from major burns have improved significantly, particularly for injuries of greater total body surface area (TBSA). Early excision and skin grafting is known to reduce infection and decrease the severity of scarring but does not prevent it.(2) Burn injuries that have not healed within 21 days have a greater likelihood of developing scars.(3) Almost invariably, burn survivors with wounds which heal slowly develop symptomatic, life-changing hypertrophic burn scarring (HBS).

HBS impacts patients both physically and psychologically. Physical symptoms include itch, pain, tightness and limitation of joint mobility. Psychological symptoms include issues with aesthetic appearance and body image, insomnia, heightened emotion and low self-esteem. Both often lead to workplace absenteeism and psychosocial issues.(4) The need to improve outcomes for burns survivors with HBS has been described as, "The greatest unmet challenge after burn injury."(5)

HBS is difficult to treat. Few randomised controlled trials exist to inform evidence-based scar management. This leads to a lack of consensus globally as to the optimal treatment regimen.(6) HBS treatment is further confounded by factors such as variable scar presentation, and non-standardised, multi-modal treatment.

Standard of care (SC) treatment includes moisturisation, silicone gel, pressure therapy, corticosteroid injection, and splinting. Pulsed dye laser (PDL) and ablative fractional laser (AFL) treatment are used based on anecdotal and case-control study evidence.(7) Randomised controlled trials of laser treatment for HBS have shown the efficaciousness of carbon dioxide AFL.(8,9) However, clearer evidence is required for the effect of early PDL and this study will focus on PDL alone.

There are fundamental differences between PDL and AFL for parameters such as wavelength and power, which determine both their mechanism of tissue interaction and their effect on scar symptoms. AFL works to ablate tissue by vaporisation in a highly localised spatial orientation. It can reduce volume, thickness and stiffness of HBS through the creation of microthermal zones.<sup>7</sup> Conversely, PDL disrupts the neovascularisation which drives the formation of HBS.(10) This implies that PDL could be most effective by its implementation during the early stages of scar maturation. Subsequently, scar progression may be diminished by dampening of the inflammatory and proliferative phases, and indeed where redness persists. In this way, the scar maturation may be shortened, and the final scar outcome may be improved in respect of redness, itch, pliability, thickness and texture.(11-13) Early scar intervention is recommended, underpinned by the premise that it is easier to prevent an excessive and dysfunctional microcirculation than to treat it once formed.(14)

The Early Laser for Burn Scars (ELABS) trial hypothesised that early PDL treatment of HBS has increased benefit than when it is established.(15) The aim of ELABS was to assess early PDL treatment of HBS within three months of wound healing, as defined by complete epithelialisation. The protraction of time-point for "early" initiation of PDL to less than 3 months saw a compromise. The logistics of identification and enrolment of recruits needed sufficient time, and consideration was made that PDL treatment of newly healed skin may induce wound regression. The clinical effectiveness and cost-effectiveness of this approach, in conjunction with standard care, were investigated compared to standard care alone. Both scar quality and quality of life (QoL) were measured to evaluate the effect on scar outcome from the patient's perspective.

### Methods

### Study design

A national, multicentre parallel arm randomised controlled trial was conducted across seven National Health Service (NHS) hospitals in the United Kingdom. ELABS was approved by The South-West Research Ethics Committee (REC reference 21/SW/0049). The protocol was published:(16) https://doi.org/10.3310/nihropenres.13234.1

A Patient and Public Involvement (PPI) cross-sectional group of 18 people (6 male, 12 female; mean age (range): 44 (16 to 79)) years was consulted on study design. The session was overseen by an independent facilitator. The group agreed that ELABS was necessary, as all patients who received PDL for burn scars perceived benefit over SC. The group voted for early PDL as the study intervention (10 vs. 8) in conjunction with SC. The control was SC alone as sham laser treatment was deemed non-viable due to the associated inherent stimuli of laser treatment. The group felt that PDL could be delayed by 6 months for the control arm as it is known to be effective where redness persists.(17) There was no perceived detriment for delayed treatment as this time frame was commensurate with the current laser treatment pathway. The PPI group was consulted, remained informed and gave feedback throughout the study.

### **Participants**

Patients with burn injuries of greater than 1% total burn surface area (TBSA) were eligible if they were treated with skin grafts or had conservatively managed wounds or donor sites which: had delayed healing of more than two weeks; had potential for HBS; were suitable for scar management therapy; and were within three months of the wound healing, as defined at the time point of full epithelialisation when dressings were no longer required. Patients were not considered eligible for inclusion if they were: unable to give informed consent; below 16 years-of-age; or prone to, or had a family history of, keloid scarring.

Participants gave written consent having been provided with all relevant information through both patient information sheets and in-person consultations with the recruitment team. Demographic data were obtained at baseline from the patient and their clinical records. Age and gender were recorded. Skin typing was evaluated using the standard sixteen group classification of ethnicity currently used in the UK, in addition to completion of the Fitzpatrick skin type scale by the assessor and participant.(18) The following parameters known to affect the

likelihood of scarring were also recorded: depth of burn; anatomical location, categorically defined as head/neck, torso or limbs; TBSA; aetiology of the burn injury; and time taken for the wound to heal.

Where multiple scars were present, the scar having the greatest impact, as reported by the patient, was defined as the 'study scar'. Only one scar per patient was included. Whichever study group the patient was assigned to, the same study scar was assessed and treated each time. The study scar and two regions of interest (ROI) were selected at baseline. The approximate size of the study scar was up to 500cm<sup>2</sup>, but typically, around 100-250cm<sup>2</sup>. The minimum size for the study scar was a 4cm square, which was the defined size of a region of interest ('scar ROI') within the study scar. The 'comparison ROI' was identified as a contralateral, unburnt area of skin of similar size. If the contralateral area was burnt or scarred, then an unburnt area proximal to the scar ROI was selected. Each ROI was used for the colour measurements only. Photographs were taken at baseline to identify the location of the study scar and the ROIs to precisely relocate these areas at subsequent assessments.

#### **Randomisation and masking**

Blinded assessments of observer-rated Patient and Observer Scar Assessment Scale (POSAS) and colour measurement were performed by a trained healthcare professional, such as burn surgeon, therapist, nurse or scientist, at baseline prior to their allocation. On completion of baseline data entry, participants were allocated to a trial arm using a randomisation tool within a secure web application (REDCap Cloud). Randomisation was in a 1:1 ratio, stratified by study centre and using random permuted blocks of varying size from 2 to 6.

Allocation status of the participant was communicated by e-mail to the principal investigator (PI) and their delegated treatment team. Allocation was revealed to the participant by the PI, or delegate, but was masked from the blinded assessor. Participants were instructed not to divulge their allocation to the blinded assessor at primary endpoint. No deviations to protocol were recorded for unblinding.

#### Procedures

#### Control arm

The control arm received SC alone at 0, 6 & 12 weeks, where week 0 was within two weeks of allocation. SC treatment was dependent upon scar maturation and clinical need. It included: moisturisation and massage; silicone gels, topical or sheeting; and compression garments.

### Intervention arm

The intervention arm received a course of three PDL treatments at intervals of 6 weeks (0, 6 & 12 weeks), in addition to SC. The treatments were performed in either order for each study visit. The PDL (Cynergy, Cynosure, Westford, MA, USA or Vbeam, Syneron Candela, USA) treatment settings used for Fitzpatrick skin types I-III and low IV were: wavelength, 595 nm; spot size, 10 mm; pulse duration, 0.5 or 0.45 milliseconds; energy fluence, 5 - 9 J cm<sup>-2</sup>; 10% overlap permitted; single pass.

Laser treatment was performed by a trained laser operator. The energy fluence was selected, and increased, to produce a moderate to strong purpura without the presence of skin blanching. Once the desired response was

observed, the operator treated the entire study scar. Previous laser settings were used at subsequent treatments, but the operator could increase the fluence until the desired response was again achieved.

For darker skin types with high type IV or V-VI, the pulse duration was increased to 6 milliseconds at the same energy range to reduce the risk of pigmentation changes. It was acknowledged in the patient information leaflet that the desired clinical effect could be reduced by the energy absorption of the competing chromophore of melanin that is increased in darker skin types.

### **Excluded Treatments**

While some treatments (AFL, non-ablative fractional laser (NAFL), micro-needling, scar revision or skin grafting) were not permitted on the study scar, they were permitted for areas of scarring situated in a different anatomical area to the study scar, as defined by head/neck, torso, upper limbs or lower limbs.

### Outcomes

All outcomes, apart from scar colour measurements and observer-rated POSAS, were reported by the participant. Each visit was performed at the respective site. Each participant attended for assessment and treatment at three study visits of 0 (baseline), 6 and 12 weeks, and at the fourth visit for assessment only at the primary endpoint of 6 months. At each assessment, the participant acclimatised for at least 20 minutes to allow skin blood flow and temperature to equilibrate. They remained seated during the assessment.

The primary outcome was patient-rated scar quality (POSAS 2.0 questionnaire, www.posas.org) at 6 months.(19,20) POSAS has been shown to be a valid, reliable and feasible tool for the evaluation of scars. Patient-rated POSAS was captured at each visit. Each of the 6 individual items of POSAS is rated on a 10-point (1 to 10) score. The total score ranges from 6 to 60, where a higher score implies a worse scar quality.(19)

Secondary outcomes were reported at baseline and primary endpoint of 6 months, unless stated:

- 1. Blinded observer-rated scar quality (POSAS v2);
- 2. Patient-rated scar quality (POSAS v2) was also reported at 6 weeks and 12 weeks;
- 3. Scar colour using a colorimeter (DSM III, Cortex, Denmark).(21) This measured separate values of Erythema (E) and Melanin (M), which were performed three times at each visit, and then averaged for each ROI. For the colour analysis, the difference in measured value of both E & M between the scar and comparison ROIs was used. Higher values of E represent increased (worse) redness or inflammation, and higher values of M represent increased pigmentation. Increased or decreased pigmentation may be an undesirable effect of scarring whereas post-inflammatory hyperpigmentation (PIH) may be an adverse event of caused by PDL treatment;
- 4. QoL: Assessed and analysed using the burn-specific CARe scale questionnaire (Centre for Appearance Research, Bristol, UK) with 14 subscales;(22)
- QoL: Further assessed by a short form survey (SF-12, QualityMetric, RI, USA) to calculate Quality Adjusted Life Years (QALYs) using SF-6D.(23) Incremental cost per QALY was then derived from SF-12 using SF-6D;

- 6. Participant's perception of change in scar quality reported at primary endpoint only. This was a seven-point ordinal response to the question "*In your opinion, what is the overall difference in your 'study scar'?*" ("very much worse", "much worse", "a little worse", "the same", "a little better", "much better" and "very much better"). The measure was dichotomised for analysis into better scar quality (improvement) versus the same/worse scar quality.
- 7. Healthcare resource use reported at primary endpoint only; captured in two ways. Data on secondary care resource use, for example clinic visits or resource requirements for PDL delivery, were collected using pro-forma. Primary care resource use data (e.g. visits to doctor, and additional personal expenditures, burn care products and travel) were collected using a patient completed questionnaire at primary endpoint. It was assumed that a PDL service was already in place in the cost analysis.

The schedule for the assessments is reported elsewhere.(16)

ELABS also explored patient experience including social and psychosocial impact. A sample of participants (n = 20, ten in each arm) received a telephone interview conducted by an experienced qualitative researcher after the participant completed ELABS.(16) This will be published in a separate article.

### Statistical analysis

No published data were found on the minimal clinically important difference for the patient-reported POSAS to calculate sample size. A one-point improvement on each of the six items, overall change of 6 points, was deemed an important improvement in scar quality by the PPI group. Based on this effect size, the trial required 60 participants in each arm to provide 90% power, assuming 2-sided 5% level of significance and a standard deviation of 10. This was increased to 150 participants to account for a 20% attrition rate.

Analyses were undertaken using statistical software (Stata version 18, Statacorp, Texas, US) and in accordance with the pre-specified statistical analysis plan signed off by the ELABS team and trial steering committee (TSC). Baseline characteristics and outcome data were reported using standard summary statistics. Effect estimates were reported with 95% CIs and p-values. Significance tests were 2-sided at the 5% level. Participants were analysed in the arm they were randomised to regardless of whether treatment was completed in keeping with the intention-to-treat principle. The main analyses used a complete case approach. Linear regression was used to compare continuous outcomes between trial arms, reporting the mean difference. Logistic regression was used to compare binary outcomes between trial arms, reporting the odds ratio. Unadjusted analyses and analyses adjusted for study site, burn scar location (head/neck versus torso versus limbs), age, and, where measured, the baseline outcome score, were undertaken.

Tests of interaction were carried out to compare the intervention effect on the primary outcome across subgroups defined by scar location and age group (16 to 24 versus 25 to 64, versus 65+). These sub-group analyses were pre-specified in the statistical analysis plan. Additional *post hoc* sub-group analyses were performed to investigate whether the intervention effect differed across subgroups defined by Fitzpatrick skin type: one

analysis where the effect for skin type categories I/II/III was compared to that for IV/V/VI and another where the effect for skin type categories I/II was compared to that for III/IV/V/VI.

Several sensitivity analyses were undertaken. A per-protocol analysis of the primary outcome was carried out, excluding intervention arm participants who did not complete any of the three laser treatment sessions. The complier average causal effect (CACE) for the primary outcome, defined as the effect of the intervention in the sub-population of participants that completed all three laser treatment sessions, was estimated with confidence intervals obtained using the bootstrap method. The primary outcome analysis was also repeated including only participants who provided outcome data within two weeks of the date that the 6-month follow-up assessment was due. Finally, analyses of the primary and secondary outcomes were repeated based on analysing multiply imputed datasets. Fifty datasets were imputed using the multivariate normal imputation method. The imputation model included all outcomes at all study waves, trial arms status, the adjustment factors and the auxiliary variable number of laser treatment sessions completed.

A cost-utility analysis (CUA) was conducted from an NHS Personal Social Services (PSS) perspective over the 6-month time horizon. QALYs were generated using the SF-6D utility algorithm, estimated from SF-12 data collected at baseline and 6 months using an area under the curve approach. Costs were calculated from patient reported resource use and Case Report Forms with a price year of 2022. Differences in costs and QALYs were estimated using seemingly unrelated regression, adjusting for baseline score (SF-6D only), age, gender, scar location and study centre. 95% confidence intervals were constructed using 5,000 bootstrap replications.

A TSC and a Data Safety and Monitoring Committee convened throughout the trial to oversee conduct, change and progress of the study. Trial oversight, database design and data management were provided by a Clinical Trials Unit (ExeCTU, Exeter, UK). The trial was registered with International Standard Randomised Controlled Trial Number registry (ISRCTN14392301).

### Role of the funding source

The funder of the trial had no role in study design, data collection, analysis, interpretation of results, or writing of the report. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR or the Department of Health and Social Care.

### Results

A total of 153 participants were recruited between Nov 17, 2021, and Jun 30, 2023; 138 were then included in the final complete case analysis (Figure 1). For the 15 patients who did not complete the study, 11 (7·2%) were lost to follow-up, three (1·3%) moved away from area, and one deceased from unrelated illness (0·7%). Attrition was better than predicted (20%) at 9·8% and there were no withdrawals from the study. The dataset was less complete for objective colour measurement (41 in intervention arm, 40 in control arm) with missing data for 57 participants. This was due to cross-infection concerns and technical issues related to the instrument.

The participant baseline characteristics are shown in Table 1. There was a similar distribution between groups in terms of gender, ethnicity, total burn surface area, burn depth, time taken to heal, and Fitzpatrick skin type. The percentage of participants aged 65+ years was twice as great in the intervention group (19.5% versus 9.2%). There were only three participants (2%) with darkest skin types V-VI. There were both more injuries (50% versus 40.3%) and fewer chemical injuries (3.9% versus 14.3%) in the control group, as well as more burn injuries to the torso in the intervention group (29.9% versus 18.4%). A lower initial mean erythema score was seen in the intervention group (7.3 versus 8.4).

The main outcome analysis results are reported in Table 2 for the complete case analyses. Analyses of imputed datasets provided similar results. There was a statistically significant difference for the primary outcome of patient-rated POSAS at 6 months in favour of the intervention arm (adjusted mean difference (AMD) =  $-4 \cdot 4$ ; 95% CI:  $-8 \cdot 7$  to  $-0 \cdot 2$ ; p= $0 \cdot 041$ ). The findings were similar for the per protocol analysis (AMD =  $-4 \cdot 3$ ; 95% CI:  $-8 \cdot 6$  to  $0 \cdot 1$ ; p= $0 \cdot 054$ ), the complier average causal effect analysis (AMD =  $-4 \cdot 5$ ; 95% CI:  $-9 \cdot 9$  to  $-0 \cdot 3$ ) and the intention-to-treat analysis based on imputed data (AMD =  $-4 \cdot 5$ ; 95% CI:  $-9 \cdot 4$  to  $0 \cdot 3$ ; p= $0 \cdot 068$ ) in supplementary Table S1. When the analysis was restricted to only participants that provided outcome data within two weeks of the scheduled date there was only weak evidence of an effect (AMD =  $-5 \cdot 8$ ; 95% CI:  $-12 \cdot 8$  to  $1 \cdot 2$ ; p= $0 \cdot 104$ ). Tests of interaction indicated little evidence that the effect of PDL on the primary outcome differed across categories defined by scar location (p= $0 \cdot 627$ ) and age (p= $0 \cdot 594$ ). The *post hoc* tests of interaction indicated weak evidence that the intervention is more effective for lighter skin types based on the Fitzpatrick classification (p=0.064 and 0.048); these findings are, however, purely exploratory given they were secondary analyses and not prespecified.

There was no statistically significant difference between groups on the secondary outcome of patient-rated POSAS at 6 weeks (p=0.31) and 12 weeks (p=0.43). A greater percentage of participants in the intervention arm reported an improvement in secondary outcome of scar quality at 6 months (p=0.01). There was little evidence of a difference between the groups for the secondary outcomes of CARe QoL subscales (all p-values>0.35), observer-rated POSAS (p=0.661) and scar colour, both E (p=0.331) and M (p=0.764) values.

Missing data for the economic analysis was low. The SF-12 was completed by all participants at baseline and by 90% at follow-up. Similarly, costs over the 6-month time horizon were calculated for 90% of participants. Table 3 summarises the SF-6D utility estimates at baseline, 6 months and QALYs. Mean baseline SF-6D scores were similar between trial arms. Examining baseline scores for complete cases, QoL was higher in the control arm than the intervention arm.

At primary endpoint, health-related QoL had increased from baseline in both arms. There was a small difference between arms, favouring the intervention (adjusted mean difference 0.002, 95% CIs; -0.037: 0.04). The SF-12 Physical Component Summary and Mental Component Summary scores indicated the sample reported their mental and physical HRQL as lower than population norms at baseline. However, at primary endpoint, physical HRQL was similar to the norm in both arms. There were slight differences between arms for both component scores at 6 months and these favoured the control arm.

There was almost no difference in the secondary outcome of QALYs between arms (adjusted difference 0.0004, 95% CIs -0.0093 to 0.0102) but the intervention arm had higher costs (adjusted difference £492.76 95% CIs - 320.79 to 1306.3). The results of the base-case Cost-Utility Analysis (CUA) from an NHS PSS perspective estimated an incremental cost effectiveness ratio (ICER) of £1,142,808.62 per QALY. The ICER indicates that PDL plus SC is not cost effective compared to SC alone. At a willingness to pay threshold of £20,000 per QALY, there is a 12% chance of PDL plus standard care being cost-effective.

Total NHS and PSS cost was the outcome used in the base-case cost-effectiveness analysis, as shown in Table 4. These were higher in the intervention arm compared to the control arm at 6 months. Mean treatment costs and out of pocket costs paid by participants (e.g. parking, train costs, burn treatments) were higher in the intervention arm, driven by additional laser visits, as seen in Supplementary Table S2. Additional appointments also contributed to higher productivity costs in the intervention arm.

There were 15 adverse events (AEs); 12 in the intervention arm and three in the control arm, as shown in Supplementary Table S3. Additional results are shown in the supplementary Tables S4-S5.

### Discussion

ELABS provides evidence that early PDL treatment of HBS is beneficial for improving scar quality, as assessed by patient-rated POSAS outcome. This result was supported by the secondary outcome of participant's perception of change in scar outcome. This concurs with a systematic review regarding treatment of abnormal scars with PDL which concluded that it is superior to conventional modalities for improving overall scar appearance, but comparable when scar parameters were evaluated separately.(24) The use of a patient-rated outcome is susceptible to bias due to the inability to blind the participant to laser treatment, but scar quality impacts the patient's QoL and was deemed important by the PPI group which informed the ELABS study design. The ELABS study design chose an inter-subject comparison of HBS.(16) A limitation of this study was the lack of an intra-subject comparison, which may have both improved internal validity and mitigated variability.

The sample size was calculated based on a mean difference of 6 points between trial arms in POSAS score being clinically meaningful; in the study, the adjusted mean difference was smaller than this (4.4), albeit with a 95% confidence interval that indicates a larger true difference is plausible. The clinical effect of early PDL treatment may take longer to become apparent as this difference was not seen at 6 nor 12 weeks in ELABS. This effect may further improve with longer follow-up duration than 6 months.

ELABS recruited beyond target with a low attrition rate, contributing to high data collection completeness. A major strength of this study may be attributed to burn scar patients often remaining within the scar management pathway beyond one year and thus low attrition may be expected. This was contrary to previous findings reported in a systematic review of burn studies.(25)

The increased number of older participants (65+ years old) may represent an enrolment bias to this study. Older people tend to scar less severely, this was assumed not to affect the analysis.(26) PDL may be less effective for darkest skin types (V&VI) due to the increased presence of the competing chromophore of melanin.(27) These skin types also have increased risk of AEs, such as permanent pigmentation changes.(28) The limited recruitment meant ELABS was unable to robustly assess either the effectiveness of PDL or the safety profile for this specific sub-group. The population demographic at some sites is a contributory factor here; particularly Salisbury, Essex and to a lesser degree St Helens and Newcastle. Future ELABS studies will aim to address this representation. The similarity in melanin scores from the colorimeter and POSAS between groups shows that post-inflammatory hyperpigmentation (PIH) is not a significant adverse effect of PDL treatment, or that pigmentation caused by the scarring process itself may be a factor.

There were nine adverse events in the laser intervention group, none of these were excessive. Blistering is a rare but self-limiting side effect of PDL treatment of HBS. PIH is a known adverse event from laser, but it is transient.(29) The pain threshold may be lower for this cohort as the wound has only recently healed. No patients withdrew from ELABS for any reason. It is concluded that PDL is a safe treatment for HBS at this early stage of healing for skin types I-IV.

The observer-rated POSAS showed no significant difference for scar quality. This may have resulted either from a lack of observer training or use of different observers at baseline and endpoint, though a inter-rater reliability for this measure of 0.82 is reported.(20) Both the completeness and fidelity of the colour measurement data may have caused the unexpected result of no identified reduction in redness with PDL, where previous studies have observed this effect.(29) The latter as well as the similarity in patient-rated POSAS scores at baseline and primary endpoint for scar colour may imply that reduction in inflammation is only part of the proposed mechanism of PDL treatment. HBS may be improved as PDL stimulates cytokine and histamine release which remodels collagen.(30)

Early delivery of PDL was not shown to be cost-effective treatment in the relative short-term follow-up of 6 months. It was hypothesised that a shorter-term improvement would serve to "flatten the peak" of scar severity, expedite maturation and lead to an improved scar outcome. It was stated in the study design that 6 months duration was long enough to show any benefits of PDL and short enough to address recruitment and attrition concerns. Given that HBS continues to evolve, the initial improvement in scar quality may result in fewer costs further along in the scar management pathway. The analysis here cannot account for potential long-term savings such as reduced need for future procedures and therapy visits, or productivity losses. A longer-term follow-up than six months is required to fully investigate the effect of PDL as the HBS matures at a duration of up to two years or more, where early PDL may prove its cost-effectiveness.(2)

The study design of enrolment, and ensuing initiation of PDL, at less than 3 months meant that there was variability in duration from wound healing to initiation of PDL. This may have impacted the clinical effectiveness of PDL for each participant, as recent systematic reviews suggest that earlier implementation may

be beneficial.(31-32) It is acknowledged that, though the time for initiation of laser was set to within 3 months of wound healing, a sub-group analysis was not included for the correlation between time to initiation of laser and its clinical effect.

ELABS indicates that early PDL treatment of HBS is safe and clinically effective at improving patient-rated scar quality. This is in line with both clinical recommendations, systematic reviews and previous studies.(14,31-34) Where a PDL service is currently in use, an early PDL treatment protocol for HBS is recommended. Further research is needed to assess the long-term clinical- and cost-effectiveness of early PDL intervention.

### Ethics Committee approval.

Ethics was approved by the NHS Health Research Authority (HRA) and Health and Care Research Wales (HCRW) in the United Kingdom. REC Reference 21/SW/0049.

### Funding

This study was funded by the National Institute for Health and Care Research (NIHR201080, United Kingdom). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

#### Acknowledgements

Yvonne Wilson (University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom) and David Barnes (Mid and South Essex NHS Foundation Trust, Chelmsford, Essex, United Kingdom) were principal investigators and oversaw the conduct of the study at their respective sites. The ELABS team also want to thank all the research teams, nurses, therapists, doctors and healthcare professionals for their work in recruiting and completing the study participants. We also acknowledge the skills and contributions of the laser operators that include Tara Mack, Dorota Bulajewska, and Dr. Kay Thomas. We also want to thank the patients for agreeing to participate in ELABS on their scar journey.

Obioha Ukoumunne was supported by the National Institute for Health and Care Research Applied Research Collaboration South West Peninsula. The views expressed in this publication are those of the author(s) and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care.

#### Contributors

MB, SD, and JP designed the study. MB, SD, VH and SR planned the study. MB, SD, VH, SR, OU, KB, KA, and NB-F implemented the study. MB, VH, JP, KB, KA, KS, QF, and CL collected the data. SD, OU, KB, and NBF analysed the data. SD, OU, and KB interpreted the data. SD & OU created the data visualisations. MB wrote the first draft and manuscript revisions. MB, SD, VH, OU, JP, KB, KA, NB-F, KS, QF, and CL reviewed and edited the manuscript. All authors had full access to all the data in the study, read and approved the final version of the manuscript, and had final responsibility for the decision to submit for publication. SD and OU directly accessed and verified the underlying data reported in the manuscript.

### **Conflict of Interest**

All authors declare no competing interests. OU was supported by the NIHR Applied Research Collaboration South West Peninsula.

## **Data Sharing**

Access to shared (de-identified) data will be via the trusted data repository, Researchfish (Elsevier) and will be linked from institutional repositories. Data is supported by relevant documentation such as the data dictionary, study protocol, statistical and health economics analysis plan.

# References

- 1. Elsaie ML. Update on management of keloid and hypertrophic scars: A systemic review. *J Cosmet Dermatol*. 2021;20(9):2729-2738. doi:10.1111/jocd.14310
- Cubison TCS, Pape SA, Parkhouse N. Evidence for the link between healing time and the development of hypertrophic scars (HTS) in paediatric burns due to scald injury. *Burns*. 2006;32(8):992-999. doi:10.1016/j.burns.2006.02.007
- 3. Deitch E, Wheelan T, Rose M, Clothier J, Cotter J. Hypertrophic burn scars: analysis of variables. *J Trauma*. 1983;23(10):895-898.
- 4. Brewin MP, Homer S. The lived experience and quality of life with burn scarring-The results from a large-scale online survey. *Burns*. 2018;44(7):1801-1810. doi:10.1016/j.burns.2018.04.007
- 5. Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring: the greatest unmet challenge after burn injury. *Lancet*. 2016;388(10052):1427-1436.
- Ogawa R. The Most Current Algorithms for the Treatment and Prevention of Hypertrophic Scars and Keloids: A 2020 Update of the Algorithms Published 10 Years Ago. *Plast Reconstr Surg.* 2022;149(1):79e-94e. doi:10.1097/PRS.00000000008667
- Oosterhoff TCH, Beekman VK, van der List JP, Niessen FB. Laser treatment of specific scar characteristics in hypertrophic scars and keloid: A systematic review. J Plast Reconstr Aesthet Surg. 2021;74(1):48-64. doi:10.1016/j.bjps.2020.08.108
- Lewis CJ, Douglas H, Martin L, Deng Z, Melton P, Fear MW, et al. Carbon dioxide laser treatment of burn-related scarring: Results of the ELIPSE (Early Laser Intervention Promotes Scar Evolution) prospective randomized controlled trial. *J Plast Reconstr Aesthet Surg*. 2023;84:368-376. doi:10.1016/j.bjps.2023.06.012
- 9. Hibbard JC, Friedstat JS, Thomas SM, Edkins RE, Hultman CS, Kosorok MR. LIBERTI: A SMART study in plastic surgery. *Clin Trials Lond Engl.* 2018;15(3):286-293. doi:10.1177/1740774518762435
- Deng H, Tan T, Luo G, Tan J, Li-Tsang CWP. Vascularity and Thickness Changes in Immature Hypertrophic Scars Treated With a Pulsed Dye Laser. *Lasers Surg Med.* Published online December 2020:lsm.23366. doi:10.1002/lsm.23366
- Kono T, Erçöçen AR, Nakazawa H, Nozaki M. Treatment of hypertrophic scars using a long-pulsed dye laser with cryogen-spray cooling. *Ann Plast Surg.* 2005;54(5):487-493. doi:10.1097/01.sap.0000155276.93061.93

- 12. Chan HH, Wong DS, Ho WS, Lam LK, Wei W. The use of pulsed dye laser for the prevention and treatment of hypertrophic scars in Chinese persons. *Dermatol Surg.* 2004;30(7):987-994.
- Bloemen MCT, van der Veer WM, Ulrich MMW, van Zuijlen PPM, Niessen FB, Middelkoop E. Prevention and curative management of hypertrophic scar formation. *Burns*. 2009;35(4):463-475. doi:10.1016/j.burns.2008.07.016
- 14. Gold MH, McGuire M, Mustoe TA, Pusic A, Sachdev M, Waibel J, et al. Updated international clinical recommendations on scar management: part 2 algorithms for scar prevention and treatment. *Dermatol Surg.* 2014;40(8):825-831.
- 15. Liew S, Murison MSC, Dickson WA. Prophylactic treatment of deep dermal burn scar to prevent hypertrophic scarring using the pulsed dye laser: a preliminary study. *Ann Plast Surg.* 2002;49(5):472-475.
- 16. Brewin M, Docherty S, Heaslip V, Breheny K, Pleat J, Rhodes S. Early Laser for Burn Scars (ELABS): protocol for a multi-centre randomised, controlled trial of both the effectiveness and cost-effectiveness of the treatment of hypertrophic burn scars with Pulsed Dye Laser and standard care compared to standard care alone. *NIHR Open Res.* 2022;2:1. doi:10.3310/nihropenres.13234.1
- 17. Alster TS, Nanni C. Pulsed dye laser treatment of hypertrophic burn scars. *Plast Reconstr Surg*. 1998;102(6):2190-2195.
- 18. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. *Arch Dermatol*. 1988;124(6):869-871. doi:10.1001/archderm.124.6.869
- 19. Draaijers LJ, Tempelman FRH, Botman YAM, Tuinebreijer WE, Middelkoop E, Kreis RW, et al. The patient and observer scar assessment scale: a reliable and feasible tool for scar evaluation. *Plast Reconstr Surg.* 2004;113(7):1960-1965. doi:10.1097/01.PRS.0000122207.28773.56
- van der Wal MBA, Tuinebreijer WE, Bloemen MCT, Verhaegen PDHM, Middelkoop E, van Zuijlen PPM. Rasch analysis of the Patient and Observer Scar Assessment Scale (POSAS) in burn scars. *Qual Life Res*. 2012;21(1):13-23. doi:10.1007/s11136-011-9924-5
- van der Wal M, Bloemen M, Verhaegen P, Tuinebreijer W, de Vet H, van Zuijlen P, et al. Objective color measurements: clinimetric performance of three devices on normal skin and scar tissue. *J Burn Care Res.* 2013;34(3):e187-e194. doi:10.1097/BCR.0b013e318264bf7d
- 22. Griffiths C, Guest E, Pickles T, Hollén L, Grzeda M, White P, et al. The Development and Validation of the CARe Burn Scale—Adult Form: A Patient-Reported Outcome Measure (PROM) to Assess Quality of Life for Adults Living with a Burn Injury. *J Burn Care Res.* 2019;40(3):312-326. doi:10.1093/jbcr/irz021
- 23. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care*. 1996;34(3):220-233.
- 24. de las Alas JMG, Siripunvarapon AH, Dofitas BL. Pulsed dye laser for the treatment of keloid and hypertrophic scars: a systematic review. *Expert Rev Med Devices*. 2012;9(6):641-650. doi:10.1586/erd.12.56
- Spronk I, Legemate C, Oen I, van Loey N, Polinder S, van Baar M. Health related quality of life in adults after burn injuries: A systematic review. Zhang HL, ed. *PLOS ONE*. 2018;13(5):e0197507. doi:10.1371/journal.pone.0197507
- Colboc H, Meaume S. Scar and Scarring in the Elderly. 2020 Dec 8. In: Téot L, Mustoe TA, Middelkoop E, et al., editors. Textbook on Scar Management: State of the Art Management and Emerging Technologies [Internet]. Cham (CH): Springer; 2020. Chapter 44. Available from: https://www.ncbi.nlm.nih.gov/books/NBK586133/ doi: 10.1007/978-3-030-44766-3\_44
- 27. Visscher MO, Bailey JK, Hom DB. Scar treatment variations by skin type. *Facial Plast Surg Clin North Am.* 2014;22(3):453-462. doi:10.1016/j.fsc.2014.04.010

- 28. Tucker DI, Aden J, Renz EM, King BT, Chan RK. Quantitative assessment of pulse dye laser therapy in the management of hypertrophic burn scars. *Ann Clin Lab Res*. 2015;3(4).
- 29. Seukeran DD, Collins P, Sheehan-Dare R. Adverse reactions following pulsed tunable dye laser treatment of port wine stains in 701 patients. *Br J Dermatol*. 1997;136(5):725-729.
- Bailey JK, Burkes SA, Visscher MO, Whitestone J, Kagan RJ, Yakuboff KP, et al. Multimodal quantitative analysis of early pulsed-dye laser treatment of scars at a pediatric burn hospital. *Dermatol Surg*. 2012;38(9):1490-1496. doi:10.1111/j.1524-4725.2012.02451.x
- Karmisholt KE, Haerskjold A, Karlsmark T, Waibel J, Paasch U, Haedersdal M. Early laser intervention to reduce scar formation–a systematic review. Journal of the European Academy of Dermatology and Venereology. 2018 Jul;32(7):1099-110.
- 32. Behrouz-Pirnia A, Liu H, Peternel S, Dervishi G, Labeit A, Peinemann F. Early laser intervention to reduce scar formation in wound healing by primary intention: A systematic review. Journal of plastic, reconstructive & aesthetic surgery. 2020 Mar 1;73(3):528-36.
- Ouyang HW, Li GF, Lei Y, Gold MH, Tan J. Comparison of the effectiveness of pulsed dye laser vs pulsed dye laser combined with ultrapulse fractional CO2 laser in the treatment of immature red hypertrophic scars. J Cosmet Dermatol. 2018 Feb;17(1):54-60. doi: 10.1111/jocd.12487
- Tan J, Zhou J, Huang L, Fu Q, Ao M, Yuan L, Luo G. Hypertrophic Scar Improvement by Early Intervention With Ablative Fractional Carbon Dioxide Laser Treatment. Lasers Surg Med. 2021 Apr;53(4):450-457. doi: 10.1002/lsm.23301.



# Figure 1: ELABS CONSORT Flow Diagram

N – number of patients/participants

		-	
Table 1: Participant	baseline	characte	eristics

Variab	le/characteristic	Intervention	Control	Overall
		N = 77	N = 76	N = 153
Site				
	Birmingham, n (%)	4 (5.2)	3 (3.9)	7 (4.6)
	Bristol, n (%)	12 (15.6)	13 (17.1)	25 (16.3)
	Chelmsford, n (%)	16 (20.8)	17 (22.4)	33 (21.6)
	Chelsea, n (%)	13 (16.9)	12 (15.8)	25 (16.3)
	Newcastle, n (%)	7 (9.1)	7 (9.2)	14 (9.2)
	St Helens and Knowsley, n (%)	9 (11.7)	8 (10.5)	17 (11.1)
	Salisbury, n (%)	16 (20.8)	16 (21.1)	32 (20.9)
Gender				
	Male, n (%)	38 (49.4)	39 (51.3)	77 (50.3)
	Female, n (%)	39 (50.6)	37 (48.7)	76 (49.7)
Age				
	16 to 24, n (%)	8 (10.4)	10 (13.2)	18 (11.8)

25  to  64  n (%)	54 (70.1)	59 (77 6)	113 (73 9)
251004, n(%)	54(70.1)	7 (0 2)	22(14.4)
$00^{+}, 11(70)$	15 (19.5)	7 (9.2)	22 (14.4)
$\mathbf{W}$ White $\mathbf{p}(0)$	62(91.9)	62(91.6)	125 (91 7)
white, $\Pi(\%)$	7 (0 1)	62(81.0)	123 (81.7)
Asian, $n(\%)$	7 (9.1)	6 (7.9) 2 (2 c)	13 (8.5)
Black, $n(\%)$	2 (2.6)	2 (2.6)	4 (2.6)
Mixed, $n(\%)$	2 (2.6)	2 (2.6)	4 (2.6)
Other, n (%)	0 (0)	1 (1.3)	1 (0.7)
Missing, n (%)	3 (3.9)	3 (3.9)	6 (3.9)
Fitzpatrick skin type		<u>S</u>	
I – Pale white skin	7 (9.1)	6 (7.9)	13 (8.5)
II – White skin	38 (49.4)	34 (44.7)	72 (47.1)
III – Light brown skin	19 (24.7)	22 (28.9)	41 (26.8)
IV – Moderate brown skin	12 (15.6)	12 (15.8)	24 (15.7)
V – Dark brown skin	0 (0)	1 (1.3)	1 (0.7)
VI – Deeply pigmented dark brown to	1 (1.3)	1 (1.3)	2 (1.3)
black skin	0		
Cause of burn injury			
Thermal scald	31 (40.3)	38 (50.0)	69 (45.1)
Thermal flame	24 (31.2)	24 (31.6)	48 (31.4)
Electrical	2 (2.6)	0 (0)	2 (1.3)
Thermal contact	5 (6.5)	7 (9.2)	12 (7.8)
Thermal flash	4 (5.2)	3 (3.9)	7 (4.6)
Chemical	11 (14.3)	3 (3.9)	14 (9.2)
Friction	0 (0)	1 (.3)	1 (0.7)
Total burn surface area (percentage), median (IQR)	4 (3 to 8)	4 (2 to 9) <sup>a</sup>	4 (2 to 8) <sup>b</sup>
Time taken to heal in days (clinician report), median	50 (34 to 72)	50.5 (35.5 to	50 (35 to 73)
(IQR)		73.5)	
Burn depth			
Full thickness, n (%)	32 (41.6)	28 (36.8)	60 (39.2)
Mixed depth, n (%)	22 (28.6)	21 (27.6)	43 (28.1)
Deep dermal, n (%)	19 (24.7)	19 (25.0)	38 (24.8)
Superficial dermal, n (%)	4 (5.2)	7 (9.2)	11 (7.2)
Unknown depth. n (%)	0 (0)	1 (1.3)	1 (0.7)
Size of scar (area in cm2), median (IOR)	160 (75 to 250)	200 (95 to 265)	200 (90 to 250)
Scar location	() - · · · · · · · · · · · · · · · · · ·	(	(
Head/Neck. n (%)	3 (3.9)	3 (3.9)	6 (3.9)
Torso, n (%)	23 (29 9)	14 (18 4)	37 (24 2)
Limbs. n (%)	51 (66 2)	59 (77 6)	110 (71 9)
POSAS score – patient report mean $(SD)$	43 5 (9 3)	41 9 (10 1)	42 7 (9 7)
	тэ.э (э.э)	<b>TIJ</b> (10.1)	72.7 (9.7)

POSAS score – observer report, mean (SD)	30.3 (9.9)	31.0 (10.2)	30.6 (10.0)
Erythema score, mean (SD)	7.3 (4.4) °	8.4 (4.9) <sup>d</sup>	7.8 (4.7) <sup>e</sup>
Melanin score, mean (SD)	15.8 (6.9) <sup>c</sup>	16.3 (8.0) <sup>d</sup>	16.1 (7.5) <sup>e</sup>

<sup>a</sup> based on 75 participants (pt); <sup>b</sup> based on 152 pt; <sup>c</sup> based on 45 pt; <sup>d</sup> based on 44 pt; <sup>e</sup> based on 89 pt

	Intervention Control (SC) Ung		The other star				
Outcome	Inte (	(PDL)	Control (SC)		Unadjusted	Adjusted	
	Ν	mean	Ν	mean	mean	mean difference	р-
		(SD) /		(SD) /	difference /	/ odds ratio	value
		n (%)		n (%)	odds ratio	(95% CI)	
POSAS score – patient report	69	34.4	69	34.6	-0.2	-1.6 (-4.6 to 1.5)	0.310
at 6 weeks		(11.4)		(11.7)			
POSAS score – patient report	68	32.1	70	32.8	-0.8	-1.4 (-4.9 to 2.1)	0.427
at 12 weeks		(11.8)		(12.2)			
POSAS score – patient report	68	30.4	69	32.6	-2.2	-4.4 (-8.7 to -0.2)	0.041
at 26 weeks		(13.1)		(13.7)			
POSAS score – observer	67	22.4	62	21.9	0.5	0.6 (-2.0 to 3.1)	0.666
report at 26 weeks		(8.2)		(9.2)			
Erythema score at 26 weeks	41	4.2	40	3.9	0.4	0.7 (-0.7 to 2.1)	0.331
		(2.7)		(3.8)			
Melanin score at 26 weeks	41	10.2	40	10.2	0.006	0.5 (-2.6 to 3.6)	0.764
		(6.0)		(8.6)			
Improvement in scar quality	68	62	69	51	3.64	4.44 (1.42 to	0.010
(binary) at 26 weeks		(91.2%)		(73.8%)		13.9)	
Care Burn Scale at 26 weeks							
Wound/Scar	65	7.9	67	7.5	0.4	0.3 (-0.6 to 1.3)	0.451
Discomfort		(2.9)		(2.9)			
Physical Well-being	66	4.3	67	4.5	-0.2	-0.05 (-0.5 to 0.4)	0.847
		(1.8)		(1.6)			
Social Situations	65	7.0	68	6.7	0.3	0.4 (-0.8  to  1.5)	0.550
		(3.9)		(3.5)			
Friend Support	64	8.7	68	8.9	-0.3	-0.3 (-1.3 to 0.7)	0.556
		(3.5)		(3.4)			
Work Life	66	7.4	68	7.0	0.5	0.05 (-0.6  to  0.7)	0.894
		(2.5)		(2.6)	0.0		0.051
Family Support	66	11.1	68	11.4	-0.3	-0.03 (-0.9 to 0.8)	0.951
	~	(2.8)	<b>C</b> 0	(2.5)	0.05	$0.4 \langle 0.4 \rangle = 1.0$	0.225
Self-worth	66	8.1	68	8.0	0.05	0.4 (-0.4 to 1.2)	0.325
D 1/2		(3.4)	<b>C</b> 0	(2.9)	0.00		0.016
Burn Wound/Scar	65	4.8	68	4./	0.08	-0.04 (-0.8 to 0.8)	0.916
Dissatisfaction	65	(2.8)	<b>C</b> 0	(2.6)	0.2	0.2(1.4, 1.0)	0.000
Intimacy/Romantic	65	8.8	68	8.6	0.2	0.2 (-1.4  to  1.8)	0.809
Relationships	~	(6.0)	<b>C</b> 0	(5.1)	0.2	0.2(1.2)(0.0)	0 (00
I rauma Symptoms	66	13.9	68	14.2	-0.3	-0.2 (-1.3 to 0.9)	0.689
No setions Marsal	65	(4.5)	60	(3.8)	07	$0.5(1.2\pm0.2)$	0.265
negative mood	05	9.0	08	9.7	-0.7	-0.3 (-1.3 to 0.3)	0.203
Desitive Creeth	65	(3.3)	67	(2.4)	0.2	$0.2(0.4 \pm 1.1)$	0.202
Positive Growth	65	4.8	0/	4.6	0.2	0.3 (-0.4  to  1.1)	0.393
		(2.5)		(2.3)			

Table 2: Analysis of Outcomes – Complete Case Analysis

*Low* scores on POSAS, erythema and melanin indicate favourable outcomes. *High* scores on Care Burn Scale subscales indicate favourable outcomes.

Table 3. Descriptive statistics of economic HRQL outcomes and SF-12 summary scores, where higher scores indicate better quality of life. PCS is the Physical component score and MCS is the Mental component score. Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.

	Control			Int	terventio	on
SF-6D Summary Score	Mean (SD)	Media n	Range	Mean (SD)	Media n	Range
SF-6D baseline	0.637 (0.132)	0.634	0.372 to 1	0.636 (0.138)	0.615	0.366 to 1
SF-6D	0.735 (0.139)	0.723	0.421 to 1	0.731	0.723	0.373 to 1
26 weeks QALYs	0.344 (0.063)	0.334	0.218 to 0.5	0.340 (0.069)	0.335	0.185 to 0.5
SF-6D baseline (complete case)	0.641	0.657	0.372 to 1	0.628 (0.14)	0.602	0.366 to 1
SF-12 summary score	Mean (SD)	Media n	Range	Mean (SD)	Media n	Range
PCS baseline	44 (10.1)	44.9	10.6 to 63.4	43.6 (9.35)	44.8	23.5 to 62.3
PCS week 26	50.6 (8.5)	53.9	23.9 to 62	49 (9.67)	51.5	26.8 to 69
MCS baseline	44.3 (10.8)	44.8	23.4 to 70.2	43.8 (11.5)	44.6	21.1 to 64.5
MCS week 26	47.4 (10.1)	47.5	17.3 to 64.3	47.4 (12.5)	50.0	15.7 to 66.4

# Table 4. Descriptive statistics of costs

	Control			Intervention		
Costs (£)	Mean (SD)	Media	Range	Mean (SD)	Media	Range
		n			n	
NHS and PSS	1,907	1 1 20	59 4- 11 010	2,465	1 (27	215 to
	(2,417)	1,139	1,139 58 to 11,916		1,027	14,326
Treatment	310 (358)	19/	39 to 2 511	455 (401)	344	18 to 2 624
	510 (550)	1)4	57 to 2,511	455 (401)	544	40 10 2,024
Out of pocket	203 (249)	135	0 to 1 589	263 (340)	135	0 to 1 774
	200 (21))	100	0 10 1,0 05	200 (0.10)	100	0 00 1,771
Productivity	1,447	16	3.3 to	1,555	35	6 8 to 20 795
	(3,795)	10	21,398	(4,070)	55	0.0 10 20,795
All (societal	3,658	1 650	72 to 22 070	4,394	2 601	321 to
perspective)	(5,053)	1,052	12 10 23,970	(5,080)	2,001	26,798

# Table 5 Cost-utility analyses results

	Incrementa	Increment	ICER	ICER	P1 <sup>d</sup>	P2 <sup>e</sup>	NMB <sup>f</sup>	NMB <sup>g</sup>
	l cost <sup>ac</sup>	al QALY <sup>bc</sup>	(£/QAL	(bootstrapped	£20,0	£30,0	£20,00	£30,00
			Y)	£/QALY) <sup>c</sup>	00	00	0	0
Base case	492.76 (-	0.000 4(-	1,142,80	1,142,808.62	0.12	0.13	-	-
	320.79:1306	0.0093:0.01	5.70				489.77	485.61
	.3)	02)						

Societal	770.79 (-	0.0004 (-	1,961,94	1,961,955.15	0.19	0.19	-	-
perspecti	965.50:2507	0.009:0.010	2.10				714.33	710.17
ve	.09)	2)					8	8

<sup>a</sup>Adjusted for age, gender, scar location and site

<sup>b</sup>Adjusted for baseline score, age, gender, scar location and site

<sup>c</sup>Estimates derived from non-parametric bootstrap estimation using 5000 replications

<sup>d</sup>P2 probability of cost-effectiveness at thresholds £20,000

eP2 probability of cost-effectiveness at thresholds £30,000

<sup>f</sup>Net Monetary Benefit at cost-effectiveness thresholds £20,000

<sup>g</sup>Net Monetary Benefit at cost-effectiveness thresholds £30,000

### Table 6: Adverse events

Adverse event	Intervention	Control	Overall
	N = 77	N = 76	N = 153
Overall, n (%)	12 (15.6)	3 (3.9)	15 (9.8)
Blisters, n (%)	2 (2.6)	0 (0)	2 (1.3)
Excessive oedema, n (%)	0 (0)	0 (0)	0 (0)
Pigmentation change, n (%)	3 (3.9)	0 (0)	3 (2.0)
Excessive pain, n (%)	4 (5.2)	0 (0)	4 (2.6)
Scabbing, n (%)	0 (0)	0 (0)	0 (0)
Worsening, n (%)	0 (0)	0 (0)	0 (0)
Wound breakdown, n (%)	1 (1.3)	0 (0)	1 (0.7)
Excessive itch, n (%)	1 (1.3)	0 (0)	1 (0.7)
Skin infection, n (%)	1 (1.3)	0 (0)	1 (0.7)
Unrelated, n (%)	0 (0)	3 (3.9)	3 (3.9)

# **Declaration of Competing Interest**

We declare no competing interests. OU was supported by the NIHR Applied Research Collaboration South West Peninsula. The project was funded by the National Institute for Health and Care Research (NIHR201080, United Kingdom) on the Research for Patient Benefit Programme.

# Highlights

- Pulsed dye laser treatment is safe and effective for hypertrophic burn scarring
- This study had a low attrition rate of 9.8%
- Pulsed dye laser should be considered as part of the burn scar treatment algorithm in its erythematous stage.

- Long term duration of 1 year or more for follow-up is essential for assessment of burn scars
- Future studies should consider the treatment of scars for darker skin types; Fitzpatrick types 5 & 6.